about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Roche vet Jean-Jacques Ga­raud woos in­ter­na­tion­al be­liev­ers in his French star­tup's take on sep­tic shock

6 years ago
Financing
Startups

Can­cer drugs among US goods spared from tar­iffs as Chi­na is­sues first ex­emp­tions in trade war

6 years ago
China

How about a $477M biotech IPO amid Hong Kong protests? Hen­lius will find out

6 years ago
Financing
China

Wood­ford fall­out to blame for shrink­ing biotech val­u­a­tions, co-in­vestor says

6 years ago
R&D

Shed­ding non-core units while load­ing up on cash, Mallinck­rodt bags $250M in CD­MO sale

6 years ago
Deals

Alex Zha­voronkov fol­lows land­mark AI pa­per with $37M round for In­sil­i­co fea­tur­ing top-notch Chi­na VCs

6 years ago
Financing
AI

Three biotechs hunt $336M-plus in a new round of IPOs — while Der­ma­vant pulls back

6 years ago
Financing

Tony Coles sets sail on new neu­ro pur­suit at Cerev­el, steer­ing Pfiz­er spin­out as CEO

6 years ago
People

Lon­don's 4BIO Cap­i­tal un­veils first close of $150M fund ded­i­cat­ed to ad­vanced ther­a­pies

6 years ago
Financing
Cell/Gene Tx

Stephen Hahn, 'clear fron­trun­ner' for FDA com­mish job, has met with Trump — re­ports

6 years ago
People
FDA+

Genen­tech reach­es set­tle­ment with Tai­wanese biotech ac­cused of steal­ing trade se­crets — but will keep su­ing ...

6 years ago
Pharma

Pri­vate eq­ui­ty meets Chi­na biotech: PAG in­fus­es $540M to gain con­trol of Hisun's biosim­i­lar sub­sidiary

6 years ago
Deals
China

How much has the can­cer R&D fren­zy trans­lat­ed in­to drug ap­provals? A lot

6 years ago
R&D
FDA+

Ned Sharp­less in fi­nal run­ning for FDA com­mish with MD An­der­son ex­ec and Har­vard prof — re­ports

6 years ago
People
FDA+

Plot­ting clin­i­cal en­try, James Wilson's gene ther­a­py start­up brings in bil­lion­aire for $110M Se­ries B

6 years ago
Financing
Cell/Gene Tx

Nkar­ta maps out clin­i­cal, man­u­fac­tur­ing plans for CAR-NK fol­low­ing $114M round led by Sam­sara

6 years ago
Financing
Startups

Armed with promis­ing alope­cia PhII, Con­cert edges for­ward with mod­i­fied JAK in­hibitor — but safe­ty will still be ...

6 years ago
R&D

Roche stays mum about FTC, CMA re­views as $4.3B Spark deal faces yet an­oth­er de­lay. What's up?

6 years ago
Deals

Alex­ion hit by sur­prise in­ter partes re­view as Am­gen chal­lenges Soliris patents

6 years ago
Pharma

On track for first au­toim­mune drug ap­proval, Bing Yao steers As­traZeneca spin­off to $150M IPO

6 years ago
Financing

Im­mu­nicum's den­drit­ic cell ther­a­py flunks co-pri­ma­ry end­point in 'pos­i­tive' PhII

6 years ago
R&D

Af­ter dis­ap­point­ing in­vestors, Sil­la­Jen gets in­to trou­ble with Ko­re­an pros­e­cu­tors on sus­pect­ed in­sid­er trad­ing

6 years ago
R&D

Kite part­ner Hi­FiBiO clos­es $67M round for pre­clin­i­cal an­ti­body can­di­dates churned out of sin­gle-cell an­a­lyt­ics ...

6 years ago
Financing

Pur­due Phar­ma pro­pos­es $12B set­tle­ment to clean up opi­oid mess — re­port

6 years ago
Pharma
First page Previous page 91929394959697 Next page Last page
A service from the Financial Times